A Placebo-Controlled Trial of Valproate for Agitation and Aggression in Alzheimer’s Disease
Background/Aims: To assess the efficacy and tolerability of valproate for the treatment of agitation and aggression in moderate-to-severe Alzheimer’s disease (AD). Methods: This was a randomized, double-blind, placebo-controlled crossover trial of valproate in institutionalized AD patients. Patients...
Gespeichert in:
| Veröffentlicht in: | Dementia and geriatric cognitive disorders 2007-01, Vol.23 (2), p.116-119 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 119 |
|---|---|
| container_issue | 2 |
| container_start_page | 116 |
| container_title | Dementia and geriatric cognitive disorders |
| container_volume | 23 |
| creator | Herrmann, Nathan Lanctôt, Krista L. Rothenburg, Lana S. Eryavec, Goran |
| description | Background/Aims: To assess the efficacy and tolerability of valproate for the treatment of agitation and aggression in moderate-to-severe Alzheimer’s disease (AD). Methods: This was a randomized, double-blind, placebo-controlled crossover trial of valproate in institutionalized AD patients. Patients were assessed with the Neuropsychiatric Inventory (NPI) and Cohen-Mansfield Agitation Inventory at baseline and after 6 weeks of treatment with valproate and placebo, with 2 weeks between phases to allow for placebo washout and tapering. Results: Fourteen patients (8 male/6 female) aged 85.6 ± 4.5 years with baseline Mini Mental State Examination scores of 4.5 ± 4.6 and NPI agitation/aggression scores of 6.4 ± 3.5 were randomized to treatment. NPI agitation/aggression treatment change scores significantly worsened during valproate treatment compared with placebo (Z = –2.03, p = 0.04). Tolerability of valproate was also poor, with patients experiencing a significantly greater mean number of adverse events during valproate therapy compared to placebo (Z = –2.82, p = 0.005). Conclusion: Valproate is not effective for the management of agitation in moderate-to-severe AD, and may be poorly tolerated in this population. |
| doi_str_mv | 10.1159/000097757 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_karge</sourceid><recordid>TN_cdi_proquest_miscellaneous_20686767</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20686767</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-10355cddd55d12b5202737298b6e8f5a7bcb951ae069de01abf9b4c966cad6e23</originalsourceid><addsrcrecordid>eNqF0c1qFTEUB_AgSltrF64FCYKCi9EkM_laXq5fhUK7qO5kOJOcuabmTtpk7kJXvoav1ydp6r200I3ZJAd-nJzDn5DnnL3jXNr3rB6rtdSPyAHvBG-sEd3jf2_WGMbMPnlaykVVWiq7R_a55p2xrTkg3xf0LILDITXLNM05xYienucAkaaRfoN4mRPMSMeU6WIVZphDmihMvlarjKXclmGii_j7B4Y15us_fwv9EApCwWfkyQix4NHuPiRfP308X35pTk4_Hy8XJ41rLZ8bzlopnfdeSs_FIAUTutXCmkGhGSXowQ1WckCmrEfGYRjt0DmrlAOvULSH5M22bx32aoNl7tehOIwRJkyb0itjhZCa_xcKpozSSlf46gG8SJs81SV60YrOqo6pit5ukcuplIxjf5nDGvKvnrP-Npn-LplqX-4aboY1-nu5i6KC1zsAxUEcM0wulHtnOl7naqt7sXU_Ia8w34HtNzduVp3i</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>232496406</pqid></control><display><type>article</type><title>A Placebo-Controlled Trial of Valproate for Agitation and Aggression in Alzheimer’s Disease</title><source>Karger Journals</source><source>MEDLINE</source><creator>Herrmann, Nathan ; Lanctôt, Krista L. ; Rothenburg, Lana S. ; Eryavec, Goran</creator><creatorcontrib>Herrmann, Nathan ; Lanctôt, Krista L. ; Rothenburg, Lana S. ; Eryavec, Goran</creatorcontrib><description>Background/Aims: To assess the efficacy and tolerability of valproate for the treatment of agitation and aggression in moderate-to-severe Alzheimer’s disease (AD). Methods: This was a randomized, double-blind, placebo-controlled crossover trial of valproate in institutionalized AD patients. Patients were assessed with the Neuropsychiatric Inventory (NPI) and Cohen-Mansfield Agitation Inventory at baseline and after 6 weeks of treatment with valproate and placebo, with 2 weeks between phases to allow for placebo washout and tapering. Results: Fourteen patients (8 male/6 female) aged 85.6 ± 4.5 years with baseline Mini Mental State Examination scores of 4.5 ± 4.6 and NPI agitation/aggression scores of 6.4 ± 3.5 were randomized to treatment. NPI agitation/aggression treatment change scores significantly worsened during valproate treatment compared with placebo (Z = –2.03, p = 0.04). Tolerability of valproate was also poor, with patients experiencing a significantly greater mean number of adverse events during valproate therapy compared to placebo (Z = –2.82, p = 0.005). Conclusion: Valproate is not effective for the management of agitation in moderate-to-severe AD, and may be poorly tolerated in this population.</description><identifier>ISSN: 1420-8008</identifier><identifier>EISSN: 1421-9824</identifier><identifier>DOI: 10.1159/000097757</identifier><identifier>PMID: 17148938</identifier><identifier>CODEN: DGCDFX</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Aged ; Aged, 80 and over ; Aggression - psychology ; Alzheimer Disease - epidemiology ; Alzheimer Disease - rehabilitation ; Anticonvulsants - therapeutic use ; Biological and medical sciences ; Cognition Disorders - diagnosis ; Cognition Disorders - epidemiology ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Double-Blind Method ; Female ; Humans ; Institutionalization ; Male ; Medical sciences ; Middle Aged ; Muscle ; Neurology ; Neuropsychological Tests ; Original Research Article ; Pharmacology. Drug treatments ; Psychomotor Agitation - diagnosis ; Psychomotor Agitation - drug therapy ; Psychomotor Agitation - epidemiology ; Severity of Illness Index ; Valproic Acid - therapeutic use ; Vascular diseases and vascular malformations of the nervous system</subject><ispartof>Dementia and geriatric cognitive disorders, 2007-01, Vol.23 (2), p.116-119</ispartof><rights>2007 S. Karger AG, Basel</rights><rights>2007 INIST-CNRS</rights><rights>Copyright (c) 2007 S. Karger AG, Basel.</rights><rights>Copyright (c) 2007 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-10355cddd55d12b5202737298b6e8f5a7bcb951ae069de01abf9b4c966cad6e23</citedby><cites>FETCH-LOGICAL-c391t-10355cddd55d12b5202737298b6e8f5a7bcb951ae069de01abf9b4c966cad6e23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2423,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18416733$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17148938$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Herrmann, Nathan</creatorcontrib><creatorcontrib>Lanctôt, Krista L.</creatorcontrib><creatorcontrib>Rothenburg, Lana S.</creatorcontrib><creatorcontrib>Eryavec, Goran</creatorcontrib><title>A Placebo-Controlled Trial of Valproate for Agitation and Aggression in Alzheimer’s Disease</title><title>Dementia and geriatric cognitive disorders</title><addtitle>Dement Geriatr Cogn Disord</addtitle><description>Background/Aims: To assess the efficacy and tolerability of valproate for the treatment of agitation and aggression in moderate-to-severe Alzheimer’s disease (AD). Methods: This was a randomized, double-blind, placebo-controlled crossover trial of valproate in institutionalized AD patients. Patients were assessed with the Neuropsychiatric Inventory (NPI) and Cohen-Mansfield Agitation Inventory at baseline and after 6 weeks of treatment with valproate and placebo, with 2 weeks between phases to allow for placebo washout and tapering. Results: Fourteen patients (8 male/6 female) aged 85.6 ± 4.5 years with baseline Mini Mental State Examination scores of 4.5 ± 4.6 and NPI agitation/aggression scores of 6.4 ± 3.5 were randomized to treatment. NPI agitation/aggression treatment change scores significantly worsened during valproate treatment compared with placebo (Z = –2.03, p = 0.04). Tolerability of valproate was also poor, with patients experiencing a significantly greater mean number of adverse events during valproate therapy compared to placebo (Z = –2.82, p = 0.005). Conclusion: Valproate is not effective for the management of agitation in moderate-to-severe AD, and may be poorly tolerated in this population.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Aggression - psychology</subject><subject>Alzheimer Disease - epidemiology</subject><subject>Alzheimer Disease - rehabilitation</subject><subject>Anticonvulsants - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cognition Disorders - diagnosis</subject><subject>Cognition Disorders - epidemiology</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Institutionalization</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Muscle</subject><subject>Neurology</subject><subject>Neuropsychological Tests</subject><subject>Original Research Article</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychomotor Agitation - diagnosis</subject><subject>Psychomotor Agitation - drug therapy</subject><subject>Psychomotor Agitation - epidemiology</subject><subject>Severity of Illness Index</subject><subject>Valproic Acid - therapeutic use</subject><subject>Vascular diseases and vascular malformations of the nervous system</subject><issn>1420-8008</issn><issn>1421-9824</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqF0c1qFTEUB_AgSltrF64FCYKCi9EkM_laXq5fhUK7qO5kOJOcuabmTtpk7kJXvoav1ydp6r200I3ZJAd-nJzDn5DnnL3jXNr3rB6rtdSPyAHvBG-sEd3jf2_WGMbMPnlaykVVWiq7R_a55p2xrTkg3xf0LILDITXLNM05xYienucAkaaRfoN4mRPMSMeU6WIVZphDmihMvlarjKXclmGii_j7B4Y15us_fwv9EApCwWfkyQix4NHuPiRfP308X35pTk4_Hy8XJ41rLZ8bzlopnfdeSs_FIAUTutXCmkGhGSXowQ1WckCmrEfGYRjt0DmrlAOvULSH5M22bx32aoNl7tehOIwRJkyb0itjhZCa_xcKpozSSlf46gG8SJs81SV60YrOqo6pit5ukcuplIxjf5nDGvKvnrP-Npn-LplqX-4aboY1-nu5i6KC1zsAxUEcM0wulHtnOl7naqt7sXU_Ia8w34HtNzduVp3i</recordid><startdate>20070101</startdate><enddate>20070101</enddate><creator>Herrmann, Nathan</creator><creator>Lanctôt, Krista L.</creator><creator>Rothenburg, Lana S.</creator><creator>Eryavec, Goran</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>88J</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2P</scope><scope>M2R</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20070101</creationdate><title>A Placebo-Controlled Trial of Valproate for Agitation and Aggression in Alzheimer’s Disease</title><author>Herrmann, Nathan ; Lanctôt, Krista L. ; Rothenburg, Lana S. ; Eryavec, Goran</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-10355cddd55d12b5202737298b6e8f5a7bcb951ae069de01abf9b4c966cad6e23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Aggression - psychology</topic><topic>Alzheimer Disease - epidemiology</topic><topic>Alzheimer Disease - rehabilitation</topic><topic>Anticonvulsants - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cognition Disorders - diagnosis</topic><topic>Cognition Disorders - epidemiology</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Institutionalization</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Muscle</topic><topic>Neurology</topic><topic>Neuropsychological Tests</topic><topic>Original Research Article</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychomotor Agitation - diagnosis</topic><topic>Psychomotor Agitation - drug therapy</topic><topic>Psychomotor Agitation - epidemiology</topic><topic>Severity of Illness Index</topic><topic>Valproic Acid - therapeutic use</topic><topic>Vascular diseases and vascular malformations of the nervous system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Herrmann, Nathan</creatorcontrib><creatorcontrib>Lanctôt, Krista L.</creatorcontrib><creatorcontrib>Rothenburg, Lana S.</creatorcontrib><creatorcontrib>Eryavec, Goran</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Science Database</collection><collection>Social Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Dementia and geriatric cognitive disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Herrmann, Nathan</au><au>Lanctôt, Krista L.</au><au>Rothenburg, Lana S.</au><au>Eryavec, Goran</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Placebo-Controlled Trial of Valproate for Agitation and Aggression in Alzheimer’s Disease</atitle><jtitle>Dementia and geriatric cognitive disorders</jtitle><addtitle>Dement Geriatr Cogn Disord</addtitle><date>2007-01-01</date><risdate>2007</risdate><volume>23</volume><issue>2</issue><spage>116</spage><epage>119</epage><pages>116-119</pages><issn>1420-8008</issn><eissn>1421-9824</eissn><coden>DGCDFX</coden><abstract>Background/Aims: To assess the efficacy and tolerability of valproate for the treatment of agitation and aggression in moderate-to-severe Alzheimer’s disease (AD). Methods: This was a randomized, double-blind, placebo-controlled crossover trial of valproate in institutionalized AD patients. Patients were assessed with the Neuropsychiatric Inventory (NPI) and Cohen-Mansfield Agitation Inventory at baseline and after 6 weeks of treatment with valproate and placebo, with 2 weeks between phases to allow for placebo washout and tapering. Results: Fourteen patients (8 male/6 female) aged 85.6 ± 4.5 years with baseline Mini Mental State Examination scores of 4.5 ± 4.6 and NPI agitation/aggression scores of 6.4 ± 3.5 were randomized to treatment. NPI agitation/aggression treatment change scores significantly worsened during valproate treatment compared with placebo (Z = –2.03, p = 0.04). Tolerability of valproate was also poor, with patients experiencing a significantly greater mean number of adverse events during valproate therapy compared to placebo (Z = –2.82, p = 0.005). Conclusion: Valproate is not effective for the management of agitation in moderate-to-severe AD, and may be poorly tolerated in this population.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>17148938</pmid><doi>10.1159/000097757</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1420-8008 |
| ispartof | Dementia and geriatric cognitive disorders, 2007-01, Vol.23 (2), p.116-119 |
| issn | 1420-8008 1421-9824 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20686767 |
| source | Karger Journals; MEDLINE |
| subjects | Aged Aged, 80 and over Aggression - psychology Alzheimer Disease - epidemiology Alzheimer Disease - rehabilitation Anticonvulsants - therapeutic use Biological and medical sciences Cognition Disorders - diagnosis Cognition Disorders - epidemiology Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Double-Blind Method Female Humans Institutionalization Male Medical sciences Middle Aged Muscle Neurology Neuropsychological Tests Original Research Article Pharmacology. Drug treatments Psychomotor Agitation - diagnosis Psychomotor Agitation - drug therapy Psychomotor Agitation - epidemiology Severity of Illness Index Valproic Acid - therapeutic use Vascular diseases and vascular malformations of the nervous system |
| title | A Placebo-Controlled Trial of Valproate for Agitation and Aggression in Alzheimer’s Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T07%3A42%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Placebo-Controlled%20Trial%20of%20Valproate%20for%20Agitation%20and%20Aggression%20in%20Alzheimer%E2%80%99s%20Disease&rft.jtitle=Dementia%20and%20geriatric%20cognitive%20disorders&rft.au=Herrmann,%20Nathan&rft.date=2007-01-01&rft.volume=23&rft.issue=2&rft.spage=116&rft.epage=119&rft.pages=116-119&rft.issn=1420-8008&rft.eissn=1421-9824&rft.coden=DGCDFX&rft_id=info:doi/10.1159/000097757&rft_dat=%3Cproquest_karge%3E20686767%3C/proquest_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=232496406&rft_id=info:pmid/17148938&rfr_iscdi=true |